Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M Adjuvant in Healthy Participants ≥ 50 to ≤ 80 Years of Age

Next Previous
Search
Trial Profile

A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M Adjuvant in Healthy Participants ≥ 50 to ≤ 80 Years of Age

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NanoFlu/NVX CoV 2373 combination vaccine-Novavax (Primary) ; Influenza virus vaccines
  • Indications COVID 2019 infections; Influenza virus infections
  • Focus Adverse reactions
  • Sponsors Novavax

    • Most Recent Events

    • 16 Oct 2024 According to a Novavax media release, trial completed in July 2023.
    • 09 May 2024 Status changed from active, no longer recruiting to completed.
    • 30 Dec 2023 According to a Novavax media release, Initial results of the trial are expected mid-year 2023, These data will inform the Phase 3 trials for both influenza stand-alone and COVID-19-influenza combination candidates.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top